The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf122 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Natalia Chamorro-Pareja und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Nivolumab, Adrenal Insufficiency, Melanoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Context
Adrenal insufficiency from hypophysitis is a complication of immune checkpoint inhibitor (ICI) therapy. However, the risk associated with relatlimab, a lymphocyte-activation gene 3 inhibitor, is unknown. Relatlimab was approved in 2022 in combination with nivolumab for the treatment of unresectable or metastatic melanoma.
Objective
To determine the prevalence, identify risk factors, and characterize the clinical presentation of central adrenal insufficiency in patients receiving relatlimab-nivolumab compared to nivolumab alone.
Methods
Retrospective analysis of Mass General Brigham healthcare system patients who received relatlimab-nivolumab from 2015 to 2023 matched by age, sex, and race to individuals receiving monotherapy with nivolumab, an ICI with a risk of hypophysitis of <1%.
Results
Adrenal insufficiency was diagnosed in 10 patients (8%) after relatlimab-nivolumab administration and in 1 patient (<1%) after nivolumab monotherapy (P = .00056). Within the relatlimab-nivolumab group, median age and sex were comparable in patients who developed adrenal insufficiency compared to those who did not. The median number of doses received by subjects who developed adrenal insufficiency was 7 (4-10) compared to 3 (2-6) in those who did not (P = .03). The most common presenting symptoms were fatigue, anorexia, nausea, and vomiting. No patients were diagnosed with additional anterior pituitary hormone deficiencies or arginine vasopressin deficiency, though not all patients were evaluated for these diagnoses.
Conclusion
This study is the first cohort analysis of hypophysitis in patients treated with relatlimab-nivolumab compared to nivolumab monotherapy. Combination treatment with relatlimab-nivolumab confers a significantly higher risk of developing adrenal insufficiency, likely secondary to hypophysitis, compared to nivolumab alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
ORCID-Profile: Natalia Chamorro-Pareja, Karen K Miller
Förderung
- NIDDK NIH HHS
Zitieren
APA
Chamorro-Pareja, N., Faje, A. T., & Miller, K. K. (2025). The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf122
Vancouver
Chamorro-Pareja N, Faje AT, Miller KK. The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf122
BibTeX
@article{ChamorroPareja2025,
author = {Chamorro-Pareja, Natalia and Faje, Alexander T and Miller, Karen K},
title = {The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf122}
}
EUVIMED